ProscaVax Vaccine Safe for Recurrent Prostate Cancer Patients, Phase 1a/1b Trial Shows

ProscaVax Vaccine Safe for Recurrent Prostate Cancer Patients, Phase 1a/1b Trial Shows
ProscaVax, a cancer vaccine developed by OncBioMune Pharmaceuticals, is safe for the treatment of recurrent prostate cancer patients, data from a Phase 1a/1b trial shows. The vaccine did not cause any serious adverse events, and did not induce any dose-limiting adverse events during the first 30 days after vaccination, meeting the trial's primary endpoint, according to the company. ProscaVax provides immunization toward the prostate specific antigen (PSA). To do so, the vaccine contains the PSA protein, together with two immune system activators, interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF). Because prostate cancer cells have high levels of PSA, the approach is
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *